Aachen, January 23, 2018 – Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will continue to commercialize Nexplanon®/Implanon NXT® throughout that region.
Aachen, Germany, January 19, 2018 – Grünenthal announced today that Adhesys Medical GmbH, a wholly-owned subsidiary of the Grünenthal Group, has received CE-Certification for MAR-CUTIS (Flix®). Flix® is a topical skin adhesive for surgical use and the first product from Grünenthal’s innovative pipeline of surgical sealants. Further products, especially for use inside the body, are under development (MAR-VIVO product family).
Aachen and Beijing, January 15, 2018 – Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market and distribute Grünenthal’s Tramal® (tramadol) in China from May 1, 2018.
Aachen, Germany, December 4, 2017 – The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards.
Aachen, Germany, November 16, 2017 – Many patients who suffer strong or persistent pain receive inadequate relief from therapy. Improving pharmacotherapy and management for refractory pain is a so enormously complex problem that only concerted approaches which link together groups with different relevant expertise are likely to have success in discovering and developing novel and effective analgesics. Grünenthal, aiming at driving new solutions in pain, organized and leads such a partnership with three research groups from the Institute for Neurosciences and Medicine (INM) of the Research Centre Jülich, and with Taros Chemicals, a firm specialized in chemical design and synthesis. Together they designed an ambitious project which could pave the way to analgesic drugs with novel dual modes of action which target causes of refractory pain.
Aachen, Germany, October 30, 2017 – The Grünenthal Group announced today that the company renewed its syndicated loan facility on October 20, 2017. For the next five years, the company can access € 400 million of available loan granted by a bank consortium. In the course of the renewal the Grünenthal Group was able to achieve significantly improved terms and conditions, including lower loan margins. This syndicated loan facility is an essential pillar of the company’s financing strategy, which also includes the recently issued promissory note (Schuldscheindarlehen).
Copenhagen, 7 September, 2017. Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of the European Pain Federation EFIC®, young scientists from across Europe presented the results of their pain research projects, which focus on novel ideas with the potential for achieving major advances in pain Management.
Aachen, Germany, May 09, 2017. The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017.
Aachen, Germany, April 7, 2017. The Grünenthal Group today announced the acquisition of Adhesys Medical GmbH and its US-based affiliate Adhesys Medical Inc., a Medical Device Startup company focused on the development of adhesives used in surgery. Through this acquisition, Grünenthal has obtained the worldwide development and commercialization rights of an innovative pipeline of surgical sealants together with the underlying technology platform. The first innovative topical skin adhesive is expected to receive European-wide CE Marketing Certification within the next 12 months.
Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant authorities (INVIMA/ANVISA/COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.